GSK Wins $235M Verdict Against Teva In Coreg Patent Fight
Teva Pharmaceuticals USA Inc. should pay GlaxoSmithKline LLC more than $235 million for willfully infringing a patent tied to the hypertension drug Coreg, a Delaware federal jury said Tuesday....To view the full article, register now.
Already a subscriber? Click here to view full article